C
Celldex Therapeutics, Inc. (CLDX)
NCM – Real Time Price. Currency in USD
35.26
+1.17 (3.43%)
At close: Jun 26, 2026, 4:00 PM EDT
35.26
-0.00 (-0.00%)
After-hours: Jun 26, 2026, 4:31 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
35.26
+1.17 (3.43%)
At close: Jun 26, 2026, 4:00 PM EDT
35.26
-0.00 (-0.00%)
After-hours: Jun 26, 2026, 4:31 PM EDT
No Data
There are no news for this stock.
Company's cash reserves $35.7M significantly exceed its total debt $1.9M, ensuring strong financial flexibility
Total current assets $459.2M exceed Total current liabilities $51.5M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$67.2M limits the company's ability to reinvest or pay down debt
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 8.92 | 6.05 | 10 | |
| Quick ratio | 8.92 | 5.63 | 10 | |
| Debt to Equity | 0.00 | 0.30 | 10 | |
| Debt to Assets | 0.00 | 1.04 | 10 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 8.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 2M | 7M | 7M | 2M | 866K |
| Gross Profit | 957K | 4M | 4M | -2M | -3M |
| Operating Income | -107M | -142M | -195M | -287M | -309M |
| Net Income | -112M | -141M | -158M | -259M | -284M |
| EBITDA | -106M | -139M | -192M | -284M | -306M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | 0.79 | -24.3 | 1.5 |
| Next quarter | N/A | -6.23 | 1.0 |
| Current year | 42.9 | -11.6 | 5.5 |
| Next year | 400.14 | -0.58 | 5.5 |
| Weighted average score | 3.4 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | -87.59 | 3.24 | 3.28 | -3.07 | 2.5 |
| Y/Y | -97.83 | -46.26 | -45.67 | -23.03 | 1.0 |
| 3y average | 38.68 | -33.79 | -21.57 | -27.82 | 3.3 |
| 5y average | 5.89 | -35.72 | -18.44 | -40.28 | 2.0 |
| Weighted average score | 2.2 | ||||
Insufficient positive free cash flow for DCF analysis
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
Insufficient positive free cash flow for DCF analysis
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |